The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature

International Journal of Drug Policy

Volumn 26, Issue 11, 2015, Pages 1050-1055

  Coats, Josh T ^a   Dillon, John F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Dried blood spot; Hepatitis C; Point of care; Testing

Indexed keywords

COHORT ANALYSIS; DRIED BLOOD SPOT TESTING; EVIDENCE BASED MEDICINE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; NONHUMAN; POINT OF CARE TESTING; POPULATION RESEARCH; PRIORITY JOURNAL; PRISON; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; HEPACIVIRUS; META ANALYSIS; POINT OF CARE SYSTEM; RISK; STATISTICS AND NUMERICAL DATA;

DRIED BLOOD SPOT TESTING; HEPACIVIRUS; HEPATITIS C; HUMANS; POINT-OF-CARE SYSTEMS; RISK; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84942200209     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.05.001     Document Type: Short Survey

References (37)

1. AASLD Recommendations for testing, managing and treating hepatitis C 2014, Retrieved from http://www.hcvguidelines.org/.
2. Abou-Saleh M.T., Rice P., Foley S. Hepatitis C testing in drug users using the dried blood spot test and the uptake of an innovative self-administered DBS test. Addictive Disorders and their Treatment 2013, 12(1):40-49. 10.1097/ADT.0b013e318253c465.
3. Arora D.R., Maheshwari M., Arora B. Rapid point-of-care testing for detection of HIV and clinical monitoring. ISRN AIDS 2013, 2013:287269. 10.1155/2013/287269.
4. Barrera J.M., Francis B., Ercilla G., Nelles M., Achord D., Darner J., et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sanguinis 1995, 68(1):15-18.
5. Bennett S., Gunson R.N., McAllister G.E., Hutchinson S.J., Goldberg D.J., Cameron S.O., et al. Detection of hepatitis C virus RNA in dried blood spots. Journal of Clinical Virology 2012, 54(2):106-109. 10.1016/j.jcv.2012.02.004.
6. Centers for Disease and Prevention Testing for HCV infection: An update of guidance for clinicians and laboratorians. Morbidity and Mortality Weekly Report 2013, 62(18):362-365.
7. Chung R.T., Baumert T.F. Curing chronic hepatitis C - The arc of a medical triumph. New England Journal of Medicine 2014, 370(17):1576-1578. 10.1056/NEJMp1400986.
8. Craine N., Parry J., O'Toole J., D'Arcy S., Lyons M. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. Journal of Viral Hepatitis 2009, 16(3):219-222. 10.1111/j. 1365-2893.2008.01061.x.
9. Craine N., Whitaker R., Perrett S., Zou L., Hickman M., Lyons M. A stepped wedge cluster randomized control trial of dried blood spot testing to improve the uptake of hepatitis C antibody testing within UK prisons. European Journal of Public Health 2014, 10.1093/eurpub/cku096.
10. De Francesco R., Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436(7053):953-960. 10.1038/nature04080.
11. Denniston M.M., Jiles R.B., Drobeniuc J., Klevens R.M., Ward J.W., McQuillan G.M., et al. Chronic hepatitis C virus infection in the United States National Health and Nutrition Examination Survey 2003 to 2010. Annals of Internal Medicine 2014, 160(5):293-300. 10.7326/M13-1133.
12. Dokubo E.K., Evans J., Winkelman V., Cyrus S., Tobler L.H., Asher A., et al. Comparison of hepatitis C virus RNA and antibody detection in dried blood spots and plasma specimens. Journal of Clinical Virology 2014, 59(4):223-227. 10.1016/j.jcv.2014.01.014.
13. Donato F., Tagger A., Gelatti U., Parrinello G., Boffetta P., Albertini A., et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. American Journal of Epidemiology 2002, 155(4):323-331.
14. Drobnik A., Judd C., Banach D., Egger J., Konty K., Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. American Journal of Public Health 2011, 101(11):2151-2155. 10.2105/AJPH. 2011.300251.
15. Goldberg D., Brown G., Hutchinson S., Dillon J., Taylor A., Howie G., et al. Hepatitis C action plan for Scotland: Phase II (May 2008-March 2011). Euro Surveillance 2008, 13(21).
16. Gretch D.R. Diagnostic tests for hepatitis C. Hepatology 1997, 26(3 Suppl. 1):43S-47S. 10.1002/hep.510260708.
17. Hayes B., Briceno A., Asher A., Yu M., Evans J.L., Hahn J.A., et al. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health 2014, 14:645. 10.1186/1471-2458-14-645.
18. Hickman M., McDonald T., Judd A., Nichols T., Hope V., Skidmore S., et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. Journal of Viral Hepatitis 2008, 15(4):250-254. 10.1111/j.1365-2893.2007.00937.x.
19. Jewett A., Al-Tayyib A.A., Ginnett L., Smith B.D. Successful integration of hepatitis C virus point-of-care tests into the Denver Metro Health Clinic. AIDS Research and Treatment 2013, 2013:528904. 10.1155/2013/528904.
20. Jewett A., Smith B.D., Garfein R.S., Cuevas-Mota J., Teshale E.H., Weinbaum C.M. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. Journal of Clinical Virology 2012, 54(3):213-217. 10.1016/j.jcv.2012.04.003.
21. Judd A., Parry J., Hickman M., McDonald T., Jordan L., Lewis K., et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology 2003, 71(1):49-55. 10.1002/jmv.10463.
22. Martin N.K., Hickman M., Hutchinson S.J., Goldberg D.J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 2013, 57(Suppl 2):S39-S45. 10.1093/cid/cit296.
23. Martin N.K., Hickman M., Miners A., Hutchinson S.J., Taylor A., Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open 2013, 3(8). 10.1136/bmjopen-2013-003153.
24. Martin N.K., Vickerman P., Foster G.R., Hutchinson S.J., Goldberg D.J., Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology 2011, 54(6):1137-1144. 10.1016/j.jhep.2010.08.029.
25. Martin N.K., Vickerman P., Grebely J., Hellard M., Hutchinson S.J., Lima V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58(5):1598-1609. 10.1002/hep.26431.
26. Mason S., Watts A., Sheils S., Koorey D. Improving access to HCV treatment: External jugular venepuncture can overcome problems with difficult venous access. International Journal of Drug Policy 2007, 18(5):433-436. 10.1016/j.drugpo.2007.01.008.
27. McLeod A., Weir A., Aitken C., Gunson R., Templeton K., Molyneaux P., et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. Journal of Epidemiology and Community Health 2014, 10.1136/jech-2014-204451.
28. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. Journal of Viral Hepatitis 2006, 13(1):34-41. 10.1111/j.1365-2893.2005.00651.x.
29. Morrill J.A., Shrestha M., Grant R.W. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Journal of General Internal Medicine 2005, 20(8):754-758. 10.1111/j.1525-1497.2005.0161.x.
30. Palmateer N.E., Taylor A., Goldberg D.J., Munro A., Aitken C., Shepherd S.J., et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One 2014, 9(8):e104515. 10.1371/journal.pone.0104515.
31. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005, 5(9):558-567. 10.1016/S1473-3099(05)70216-4.
32. Shivkumar S., Peeling R., Jafari Y., Joseph L., Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: A systematic review and meta-analysis. Annals of Internal Medicine 2012, 157(8):558-566. 10.7326/0003-4819-157-8-201210160-00006.
33. SIGN. 50: A guideline developer's handbook 2011, Healthcare Improvement Scotland, Edinburgh.
34. Smith B.D., Morgan R.L., Beckett G.A., Falck-Ytter Y., Holtzman D., Teo C.G., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Morbidity and Mortality Weekly Report 2012, 61(RR-4):1-32.
35. Tait J.M., Stephens B.P., McIntyre P., Evans M., Dillon J.F. Dry blood spot testing for hepatitis C in people who injected drugs: Reaching the populations other tests cannot reach. Journal of Hepatology 2013, 58:S204.
36. White B., Dore G.J., Lloyd A.R., Rawlinson W.D., Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study. Medical Journal of Australia 2014, 201(6):326-329.
37. Wiese M., Berr F., Lafrenz M., Porst H., Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000, 32(1):91-96. 10.1053/jhep.2000.8169.